Articles
7,669 Articles
Psychedelic Invest
/
Dec 13, 2024
PharmAla Announces Private Placement
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased...
MDMA
DoubleBlind Mag
/
Dec 12, 2024
Good Vibrations: The Top 25 Psychedelic Rock Albums
Psychedelic music had simple yet complex beginnings: All you had to do to call yourself a psych-rock artist back in the mid-to-late 1960s was put a tab of LSD on your tongue, wait an hour, then crank up the amplifier and bang out some bluesy riffs on an electric guitar. The counterculture movement...
LSD
Psychedelic Invest
/
Dec 12, 2024
MindBio Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike
Vancouver, British Columbia – December 11, 2024 –TheNewswire –MindBio Therapeutics Corp.(the “Company” or “MindBio”) (CSE: MBIO) (Frankfurt:WF6) wishes to provide an update to its shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company’s...
Psychedelic Invest
/
Dec 11, 2024
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Ontario–(Newsfile Corp. – December 10, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, today announces initial...
Psychedelic Invest
/
Dec 10, 2024
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has progressed beyond the previously-announced non-binding Letter of Intent (LOI) and executed binding agreements with Optimi Health Corp. Under...
Psychedelic Invest
/
Dec 10, 2024
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters...
DMT
Psilocybin Alpha
/
Dec 10, 2024
Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects on Lykos’ Strategy; Polish Psilocybin Study Scores $4M in Funding
As some of us draw up our wishlists for Santa’s perusal (though, apparently Saint Nicholas has been found a little worse for wear in Turkey), some psychedelics insiders are noting down their hopes for the incoming Trump administration. Since the U.S. elections last month, I have been speaking with...
Psilocybin
Psychedelics
Psychedelics Today
/
Dec 10, 2024
The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics Could Prevent Nuclear War
In this episode, Joe interviews Howard Kornfeld, MD: renowned pain medicine expert, addiction specialist, early pioneer in psychedelic medicine, and currently the director of recovery medicine at Recovery Without Walls. As a leader in the utilization of buprenorphine, he talks about how it came...
Psychedelics
DoubleBlind Mag
/
Dec 10, 2024
Should Psychedelic Researchers Disclose Personal Use of the Drugs They Study?
Scientific researchers who author papers must disclose any financial conflicts of interest when publishing their studies — like if they’re employed by companies that might profit from the subject matter being investigated. Psychedelic researchers, however, are not required to admit whether they...
DoubleBlind Mag
/
Dec 09, 2024
The First Major For-Profit Psychedelic Company Is Experiencing Major Setbacks
When the FDA denied MDMA-assisted therapy earlier this year, the shockwaves throughout the psychedelic industry were immediate and apparent. Now, Compass Pathways, another major player in the space, has announced that it is laying off roughly 30% of its workforce and delaying the Phase 3 Trials for...
MDMA
Psychedelic Invest
/
Dec 09, 2024
Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence
ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) — Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central...
DoubleBlind Mag
/
Dec 09, 2024
Santo Daime Ayahuasca Church Faces a “Me Too” Reckoning
In Rio de Janeiro, a woman is bringing a lawsuit against a prominent Santo Daime leader named Paolo Roberto for sexual assault under the guise of therapy. He is a fixture of a Santo Daime church in Rio de Janeiro and a senior figure in one particular lineage of Santo Daime, with many supporters and...
Ayahuasca
Psychedelics - Green Market Report
/
Dec 09, 2024
Relmada halts depression drug trials, shifts focus to psilocybin program amid review
Relmada Therapeutics Inc. (Nasdaq: RLMD) will halt its Phase 3 studies of depression treatment REL-1017 following a data monitoring committee evaluation, sending the company searching for strategic alternatives. The late-stage biotechnology company will discontinue both the Reliance II and Relight...
Psychedelic Invest
/
Dec 09, 2024
MindBio Announces Completion of Private Placement and Issuance of Listed Securities
Vancouver, British Columbia –TheNewswire –December 9, 2024–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),a leading clinical stage biopharmaceutical company in psychiatric medicine development using microdoses of psychedelic medicines, is...
Psychedelics Today
/
Dec 06, 2024
Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities
In this episode, Joe interviews Veronica Lightning Horse Perez: therapist, speaker, author, activist, and co-chief proponent for the Natural Medicine Health Act of 2022 (Prop 122); and Sean McAllister: attorney specializing in the regulatory, health care, business, and religious freedom aspects of...
Psychedelics - Green Market Report
/
Dec 06, 2024
Ketamine diversion rates increase according to new report
The Journal of American Medical Association (JAMA) published a report this week noting the increase in diversions of the drug ketamine. The report was authored by Joseph J. Palamar, PhD, Caroline Rutherford, MS and Katherine M. Keyes, PhD. and they obtained data on undistributed pharmaceutical...
Psychedelic Invest
/
Dec 06, 2024
Psyence Group Enters Into Agreements With Its NASDAQ-Listed Associate, Psyence Biomedical, To Settle Outstanding Obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Company“) (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the “Debt Swap Agreements“) with its NASDAQ-listed associate,...
Psychedelic Invest
/
Dec 06, 2024
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been...
Psychedelic Invest
/
Dec 06, 2024
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development...
DoubleBlind Mag
/
Dec 05, 2024
We Need Trip-Free Psychedelics in Medicine
Bad trips can ruin lives, but psychedelics might help save them. For investors, therapists, practitioners, and medical researchers working with these compounds, it has been a year of hard lessons. A charismatic but ham-handed bid to legalize MDMA-assisted therapy by Lykos Therapeutics’ was denied...
Psilocybin
LSD
DMT
MDMA
Ibogaine
Noribogaine
Psychedelics
Psilocybin Alpha
/
Dec 05, 2024
Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges, and the Future of the Field
In our latest interview, Psychedelic Alpha’s Josh Hardman speaks with Javier Muniz, MD, who recently left his post as Associate Director at the FDA’s Division of Psychiatry. In that role, Muniz was at the heart of the agency’s psychedelics learning journey and helped formulate its view on...
Psychedelics
Lucid News
/
Dec 05, 2024
NYC Memorial Planned for Lucid News Co-Founder Ken Jordan
Ken Jordan, the co-founder and editorial director of Lucid News, will be remembered by friends and family at a gathering in New York City this month. Jordan died unexpectedly on May 12, 2024 leaving this news service as his legacy. He believed in the transformative power of psychedelics for healing...
DoubleBlind Mag
/
Dec 04, 2024
Six Ways to Connect with Iboga After Ceremony
Iboga is a truly unique medicine. Not only does it have astounding neurological effects that help people overcome addiction, but it can leave you feeling as if you’ve been reborn. Yet even though this can feel miraculous, iboga isn’t a miracle cure for any physical or psychological ailment (and...
Iboga
Psychedelics
DoubleBlind Mag
/
Dec 04, 2024
Finally, A Company Verifying Which Shroom Products Are Legit
If you want to consume cannabis in a state where it is legal, you can check the packaging to find out the THC and CBD content, dominant terpene profiles, information on a strain’s lineage, and other titbits that help inform the consumer about how the experience will feel. This information...
Psilocybin
Psychedelic Invest
/
Dec 03, 2024
VA Awards $1.5M To Study MDMA for PTSD
Veterans Affairs officials announced on Tuesday a $1.5 million grant to explore MDMA-assisted therapy as a treatment for post-traumatic stress disorder (PTSD) and alcohol use disorder among veterans. This marks the department’s first government-funded research into the potential benefits of...
MDMA
Psychedelics - Green Market Report
/
Dec 03, 2024
Red Light Holland posts 40% jump in revenue, narrows losses
Canadian psychedelics company Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) cut its quarterly losses and grew sales as its mushroom and truffle business expanded across North America and Europe. Revenue reached C$1.37 million for the quarter ending Sept. 30, up 39.1% from C$983,324 in the...
Psychedelics Today
/
Dec 03, 2024
How Family Healing Shapes Veteran Recovery
In this episode, Joe interviews two members of the Heroic Hearts Project: Founder and President, Jesse Gould; and Director of Development and Head of Family Relations, Allison Wilson. Gould gives a background of Heroic Hearts Project and discusses their current projects and future goals, and Wilson...
Microdose
/
Dec 03, 2024
Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives
Enveric Biosciences announced the issuance of two new patents from the US Patent and Trademark Office (USPTO) supporting its EVM301 and EVM201 series compounds. These patents increase the total number of patents to 11 for the EVM301 series. The new patents protect novel, non-obvious,...
Psilocybin
DoubleBlind Mag
/
Dec 03, 2024
Are Colorado’s Psychedelic Regulations Too Strict—or Too Loose?
Colorado is preparing to launch its legal mushroom program amidst a bevy of concerns from both critics and advocates. Aspiring participants in the groundbreaking program, which will begin next year, have expressed worries that proposed licensing fees will be economically challenging, making it...
DoubleBlind Mag
/
Dec 02, 2024
Returning to the Body and the Psychedelic Power of Collective Memory
The Return to the Body is the key concept of the Black diaspora. When Black people reembrace the body, relish kinky hair and skin hues from brown to beige, toffee to obsidian, revel in it, squeeze from it deep pain and pleasure, a nuclear blast of energy is released that transports one to a...
LSD
Psychedelic Invest
/
Dec 02, 2024
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today...
Ketamine
Psychedelics Today
/
Dec 02, 2024
Prophecy, Psychedelics, and Power in Dune
Join us for a thought-provoking exploration of Frank Herbert’s Dune series, focusing on the spice melange as a symbol of spiritual transcendence and systemic control. This webinar examines the tension between personal faith and institutional tradition, the commodification of transcendent truth,...
Psychedelics Today
/
Nov 29, 2024
Is Cannabis a Psychedelic? Exploring the Science of Indoles, Interprening, and Intention
Most cannabis enthusiasts have experienced the wide range of possible effects, from a subtle happy high to one that floors you. The question must be asked: Is cannabis a psychedelic? And how can we make it more so? In this episode, Victoria interviews Max Montrose: Founder of the Trichome Institute,...
Cannabis
Zen Habits
/
Nov 29, 2024
A Month of Reflection
By Leo Babauta We’re entering the last month of the year, and for many of us, it’s a darker and quieter season. It’s the perfect time for reflection. I like to use December to deepen into reflection, and in my Fearless Living Academy, we do a yearly ritual that I call “Sacred Bow”...
DoubleBlind Mag
/
Nov 28, 2024
Here Are the Trippiest Movies on Amazon Prime
Psychedelics can open you up to other dimensions, inspiring you to contemplate the nature of space, time, and reality. But sometimes, all you need to accomplish the same thing is a fun, philosophical movie. Relax with one of these films when you’re ready for a trip around the universe — one you...
Psychedelics
DoubleBlind Mag
/
Nov 27, 2024
Where Did Western Psychedelic Therapy Come From, Exactly?
Humphrey Osmond, a British psychiatrist, is widely credited as the Westerner who developed the first psychedelic therapy program in the 1950s. Osmond, along with psychiatric colleague Abraham Hoffer, initially set out to study schizophrenia from a biochemical perspective; the pair noted how...
Psilocybin
LSD